InsiderTrades.com logo
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.

DRUG Insider Trading

Insider Ownership Percentage: 42.66%
Insider Buying (Last 12 Months): $2,060,428.23
Insider Selling (Last 12 Months): $0.00

Bright Minds Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Bright Minds Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bright Minds Biosciences Share Price & Price History

Current Price: $21.70
Price Change: ▼ Price Decrease of -7.1 (-24.65%)
As of 10/17/2024 01:00 AM ET

This chart shows the closing price history over time for DRUG up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Don’t Buy Another Stock Until Reading This…
From Unstoppable Prosperity   |   Ad
Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my upcoming FREE intro to investing online event, my team will be revealing the strategies I've developed over the past 37 years on Wall Street…
Click here to claim your seat at my Intro to Investing class now!

Bright Minds Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/15/2024Cormorant Asset Management, LpMajor ShareholderBuy372,591$5.53$2,060,428.23825,000View SEC Filing Icon  
See Full Table
DeFi Coin on Verge of Breakout!
From Crypto 101 Media   |   Ad
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
You can get access to the report by clicking here now…

SEC Filings (Institutional Ownership Changes) for Bright Minds Biosciences (NASDAQ:DRUG)

40.52% of Bright Minds Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DRUG by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Bright Minds Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/14/2024AdvisorShares Investments LLC188,119$0.27M0.1%+12.0%4.246%Search for SEC Filing on Google Icon
11/6/2023AdvisorShares Investments LLC167,930$0.27M0.1%-67.4%4.452%Search for SEC Filing on Google Icon
8/9/2023AdvisorShares Investments LLC515,315$0.29M0.1%+14.7%14.640%Search for SEC Filing on Google Icon
5/9/2023AdvisorShares Investments LLC449,155$0.20M0.1%+42.7%2.553%Search for SEC Filing on Google Icon
8/8/2022AdvisorShares Investments LLC289,576$0.24M0.1%+40.1%2.439%Search for SEC Filing on Google Icon
5/9/2022AdvisorShares Investments LLC206,716$0.31M0.1%+115.5%1.745%Search for SEC Filing on Google Icon
2/9/2022Checchi Capital Advisers LLC14,138$45K0.0%N/A0.119%Search for SEC Filing on Google Icon
1/31/2022AdvisorShares Investments LLC95,942$0.30M0.0%N/A0.810%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Bright Minds Biosciences logo
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
Read More on Bright Minds Biosciences

Today's Range

Now: $21.70
Low: $21.10
High: $26.00

50 Day Range

MA: $2.88
Low: $1.01
High: $38.49

52 Week Range

Now: $21.70
Low: $0.93
High: $38.49

Volume

2,584,556 shs

Average Volume

750,447 shs

Market Capitalization

$96.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Who are the company insiders with the largest holdings of Bright Minds Biosciences?

Bright Minds Biosciences' top insider investors include:
  1. Cormorant Asset Management, Lp (Major Shareholder)
Learn More about top insider investors at Bright Minds Biosciences.
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.